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Regarding “Cold visceral perfusion improves early
survival in patients with acute renal failure after
thoracoabdominal aortic aneurysm repair”
I read with great interest the article by Hassoun et al (J Vasc
Surg 2004;39:506-12), which outlines the care of patients with
thoracoabdominal aneurysms. I believe, however, that there is
some information missing. Fig 2 of the article does not clearly
convey the procedural techniques. The text is also unclear in this
regard. The authors state, “For distal aortic perfusion the left
atrium or inferior pulmonary vein was cannulated” and that the left
femoral artery was also cannulated. However, the left side of Fig 2
shows cannulation of the descending thoracic aorta, not the left
atrium.
The figure also shows a Y connector, with one arm leading to
the visceral perfusion line and the other going to the femoral
artery. There is a heat exchanger in the line going to the femoral
artery; I assume that this is just to maintain normal temperature
during distal body perfusion. There are no flow probes in the line
to the visceral perfusion, and the placement of a Y connector
beyond the Biomedicus pump may explain why patients receiving
warm perfusate suffer a greater degree of renal failure than those
receiving cold solution.
Since the heat exchanger is maintaining 37° C in the distal
body, it may be experiencing greater vasodilation than the visceral
organs; therefore, most of the blood may be flowing to the distal
body rather than to the abdominal organs. Since there is no control
of the flow in either line, the abdominal organs and the kidneys
may be subjected to much lower flow than is needed to maintain
adequate viability. In my opinion, the amount of flow to the
abdominal organs must be controlled. If the perfusion is strictly
dependent on the pressure in the distal thoracic aorta—as the
drawing seems to indicate—then there is actually no control of the
flow used to maintain the viability and function of the kidneys. If
valid information is to be obtained, then both lines—to the ab-
dominal organs and to the femoral artery—must have flow meter
probes.
The drawing on the right side of Fig 2 is titled “Cold,” and
illustrates the cold system. It shows the line for cold perfusion to
the organs passing through an ice bath. The line to the femoral
artery, however, is provided with a heat exchanger. The article does
not state whether the function of the heat exchanger is to maintain
normal temperature in the distal body or to cool the temperature
of the lower extremities and pelvis to the same temperature as the
perfusate going to the visceral organs. The illustration seems to
indicate, however, that hypothermic cooling of the abdominal
organs, as well as of the distal body, is implemented. This would
undoubtedly lower the temperature of the patient’s entire body
and may be dangerous, as body temperature may fall into the range
in which the heart may fibrillate. It would also be a challenge for
the anesthesiologist to maintain normal body temperature in the
upper part of the body.
These details need to be clarified because increased renal
failure in patients perfused with warm perfusate may be due to lack
of flow and not necessarily to the temperature of the perfusate
itself. The authors’ conclusions, therefore, may not be totally
correct. I would like to ask the authors to clarify these discrepan-
cies, which are not fully explained in the article.
J. Ernesto Molina, MD, PhD
Professor of Surgery
Division of Cardiovascular and Thoracic Surgery
Department of Surgery
University of Minnesota Medical School
Minneapolis, Minn
doi:10.1016/j.jvs.2004.04.023
Reply
It is with great pleasure that we respond to the questions posed
by Dr Molina regarding Fig 2 in our recently published article. The
left side of the original Fig 2 is a simple schematic of our initial
approach to distal aortic perfusion and direct visceral perfusion
with warm blood in a patient with a type III thoracoabdominal
aortic aneurysm (TAAA). While it is our routine to cannulate the
left atrium or left inferior pulmonary vein for distal aortic perfu-
sion, we occasionally cannulate the proximal descending thoracic
aorta during type III TAAA repairs. Our current approach is to use
cold visceral perfusion whenever possible by the insertion of a roller
pump and an ice bath into the circuit, as depicted in the right side
of the original Fig 2 and in our revised Figure (p. 206). Warm
visceral perfusion can be applied in a similar fashion but without
the ice bath. The total visceral flow rates ranged from 300 to 450
mL/min measured with a flow probe. The use of flow probes on
each individual catheter to the celiac, superior mesenteric, and
renal arteries would indeed provide useful data, but these probes,
at least to our knowledge, are not readily available. The kidney
temperature is routinely monitored, and a reduction to 15° to
20°C during cold perfusion is indicative of adequate flow. Finally,
a heat exchanger in the distal aortic perfusion circuit is used to
provide warm perfusion to the lower extremities, and we prefer to
maintain systemic temperature at a mild hypothermia (33°-34° C).
We thank the editors for the opportunity to respond to the
valid questions/concerns posed by Dr Molina, and hope that the
revised Figure (p. 206) will clarify our approach to visceral perfu-
sion during TAAA repair.
Heitham T. Hassoun, MD
Tam T.T. Huynh, MD
Hazim J. Safi, MD
University of Texas-Houston Medical School
Houston, Tex
doi:10.1016/j.jvs.2004.04.024
Regarding “Disappointing results with a new
commercially available thoracic endograft”
In the recent article by Melissano et al (J Vasc Surg 2004;39:
124-30), the authors report their limited and “disappointing”
experience with the Endofit graft (Endomed, Phoenix, Ariz) in
treating thoracic aortic disease, particularly aortic arch pathology,
in 11 patients. Endomed has reviewed these reported results
internally and with physicians familiar with the device, and takes
issue with the conclusions expressed by the authors that the results
reflect defects in the device.
Four of the 11 Endofit cases studied involved the distal aortic
arch; 3 of these patients developed complications (graft migration,
type I endoleak, and graft collapse). On the basis of our investiga-
tion and review of the postmortem photographs, it is apparent that
the migrated graft had been deployed upside down and the prox-
imal edge of the graft placed distal to the left subclavian artery in a
short neck. This off-label use of the device is not advised and is
risky.
The type I endoleak in an arch endograft and one other
associated with a stent graft in the DTA suggest that undersized
grafts were chosen. For the Endofit, we recommend 20% oversiz-
ing based on the maximum diameter of the true lumen obtained
from the computed tomography scan (not the angiogram!). The
authors did not specify how they sized the grafts in these patients.
In their last case, the endograft had to be removed after 2
weeks owing to graft collapse, which the authors imply was due to
stent fracture. However, the fractured stents were not in the
collapsed portion of the graft, but in the fully expanded distal graft
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segment that was in full apposition to the aortic wall. Moreover,
after so short a time in situ, the graft could not collapse from
material fatigue. It is more likely that mechanical strain, perhaps
during deployment, damaged the endograft. The reason for the
collapse of the proximal graft cannot be determined from the infor-
mation the authors provide, but stent fracture was not the cause.
It must be noted that we asked the hospital and the doctors for
the surgical records for each reported incident, but our requests
were denied.
Central nervous system complications related to stent-graft
repair of aortic arch lesions are widely reported and dependent on
arch anatomy, intraluminal manipulations, and large introducer
sheaths. Ramaiah et al1 reported 1 (2.7%) fatal stroke among 37
patients who underwent Endofit stent-graft repair of the thoracic
aorta for various pathoses. Of 43 patients treated with thoracic
Excluder or Talent endoprostheses by Lepore et al,2 8 (18.6%) had
strokes and 3 (7%) developed paraplegia. Bell et al3 reported stroke
in 3 (4.4%) and paraplegia in 3 (4.4%) of 67 patients treated with a
variety of second-generation thoracic stent grafts. Additional pub-
lished findings also suggest that there is no correlation between
these events and the type of endograft.
The endovascular literature recognizes a higher incidence of
complications in the early learning curve with a new procedure or
device.4,5 This is the reason that we provide a proctor to advance
the curve before use, but the authors did not use this service.
Lastly, the Milan authors conclude from their 11-patient
experience that “. . . other commercially available endografts may
be safer for endovascular treatment of thoracic aortic disease.” The
authors have used 1 other device on only 2 occasions. Neither of
these extremely small experiences is adequate to support a statisti-
cally reliable comparison. Further, the authors used the first-
generation Endofit device. Based on early clinical experience, we
have modified the device to increase its flexibility and radial
strength; more importantly, the Endofit also now comes loaded in
the delivery catheter to facilitate deployment with the appropriate
force and in the proper direction.
William M. Colone
President
Endomed, Inc
Phoenix, Ariz
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Revised Figure.
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